دورية أكاديمية
SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study.
العنوان: | SARS-CoV-2 seroepidemiology in Mongolia, 2020-2021: a longitudinal national study. |
---|---|
المؤلفون: | Chimeddorj B; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.; Institute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Bailie CR; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia., Mandakh U; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Price DJ; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.; Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, Australia., Bayartsogt B; Department of Epidemiology and Biostatistics, School of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Meagher N; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia., Altanbayar O; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Magvan B; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Deleg Z; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Gantumur A; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Byambaa O; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Nyamdavaa E; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Enkhtugs K; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Munkhbayar U; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Bayanjargal B; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Badamsambuu T; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Dashtseren M; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Amartuvshin T; Department of Family Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Narmandakh Z; Department of Immunology, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Togoo K; Department of Immunology, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Boldbaatar EA; Department of Immunology, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Bat-Erdene A; Department of Immunology, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Chimeddorj U; Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Nyamdavaa K; Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Tsevegmid E; Ministry of Health, Mongolia., Batjargal O; Department of Molecular Biology and Genetics, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Enebish O; Department of Research Planning, Ministry of Health, Mongolia., Enebish G; Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Batchuluun B; Central Clinical Laboratory, Mongolia Japan Hospital, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Zulmunkh G; Central Clinical Laboratory, Mongolia Japan Hospital, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Byambatsogt G; Department of Biochemistry, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Enebish T; Regional Office for the Western Pacific, World Health Organization, Manila, Philippines., Le LV; Regional Office for the Western Pacific, World Health Organization, Manila, Philippines., Bergeri I; World Health Organization, Geneva, Switzerland., McVernon J; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.; Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital, Australia., Erkhembayar R; Department of International Cyber Education, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia. |
المصدر: | The Lancet regional health. Western Pacific [Lancet Reg Health West Pac] 2023 Apr 10, pp. 100760. Date of Electronic Publication: 2023 Apr 10. |
Publication Model: | Ahead of Print |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101774968 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6065 (Electronic) Linking ISSN: 26666065 NLM ISO Abbreviation: Lancet Reg Health West Pac |
أسماء مطبوعة: | Original Publication: [London] : Elsevier Ltd., [2020]- |
مستخلص: | Background: The COVID-19 pandemic has global impacts but is relatively understudied in developing countries. Mongolia, a lower-middle-income country, instituted strict control measures in early 2020 and avoided widespread transmission until vaccines became available in February, 2021. Mongolia achieved its 60% vaccination coverage goal by July 2021. We investigated the distribution and determinants of SARS-CoV-2 seroprevalence in Mongolia over 2020 and 2021. Methods: We performed a longitudinal seroepidemiologic study aligned with WHO's Unity Studies protocols. We collected data from a panel of 5000 individuals in four rounds between October 2020 and December 2021. We selected participants through local health centres across Mongolia by age-stratified multi-stage cluster sampling. We tested serum for the presence of total antibodies against SARS-CoV-2 receptor-binding domain, and levels of anti-SARS-CoV-2 spike IgG and neutralising antibodies. We linked participant data with national mortality, COVID-19 case, and vaccination registries. We estimated population seroprevalence and vaccine uptake, as well as unvaccinated population prior-infection prevalence. Findings: At the final round in late 2021, 82% (n = 4088) of participants completed follow-up. Estimated seroprevalence increased from 1.5% (95% CI: 1.2-2.0), to 82.3% (95% CI: 79.5-84.8) between late-2020 and late-2021. At the final round an estimated 62.4% (95% CI: 60.2-64.5) of the population were vaccinated, and of the unvaccinated population 64.5% (95% CI: 59.7-69.0) had been infected. Cumulative case ascertainment in the unvaccinated was 22.8% (95% CI: 19.1%-26.9%) and the overall infection-fatality ratio was 0.100% (95% CI: 0.088-0.124). Health workers had higher odds for being COVID-19 confirmed cases at all rounds. Males (1.72 (95% CI: 1.33-2.22)) and adults aged 20 and above (12.70 (95% CI: 8.14-20.26)) had higher odds for seroconverting by mid-2021. Among the seropositive, 87.1% (95% CI: 82.3%-90.8%) had SARS-CoV-2 neutralising antibodies by late 2021. Interpretation: Our study enabled tracking of SARS-CoV-2 serological markers in the Mongolian population over one year. We found low SARS-CoV-2 seroprevalence in 2020 and early 2021, with seropositivity increasing over a 3-month interval in 2021 due to vaccine roll out and rapid infection of most of the unvaccinated population. Despite high seroprevalence in Mongolia amongst both vaccinated and unvaccinated individuals by end-2021, the SARS-CoV-2 Omicron immune escape variant caused a substantial epidemic. Funding: World Health Organization, WHO UNITY Studies initiative, with funding by the COVID-19 Solidarity Response Fund and the German Federal Ministry of Health (BMG) COVID-19 Research and development. The Ministry of Health, Mongolia partially funded this study. Competing Interests: We declare no competing interests. (© 2023 World Health Organization.) |
References: | Influenza Other Respir Viruses. 2022 Jan;16(1):7-13. (PMID: 34611986) Eur J Epidemiol. 2021 Jun;36(6):581-588. (PMID: 34322831) Int J Environ Res Public Health. 2021 Dec 07;18(24):. (PMID: 34948511) PLoS Med. 2022 Nov 10;19(11):e1004107. (PMID: 36355774) N Engl J Med. 2022 Apr 7;386(14):1314-1326. (PMID: 35196424) Lancet Child Adolesc Health. 2022 May;6(5):294-302. (PMID: 35189083) PLoS Med. 2021 Oct 21;18(10):e1003807. (PMID: 34673772) Lancet Reg Health West Pac. 2021 Dec;17:100317. (PMID: 34841381) Trop Med Int Health. 2022 May;27(5):515-521. (PMID: 35303386) Nat Immunol. 2022 Jul;23(7):1008-1020. (PMID: 35761083) PLoS Med. 2021 Dec 10;18(12):e1003877. (PMID: 34890407) Lancet Microbe. 2022 Jan;3(1):e52-e61. (PMID: 34806056) Lancet Public Health. 2020 Sep;5(9):e475-e483. (PMID: 32745512) Saf Health Work. 2022 Sep;13(3):263-268. (PMID: 35433073) Int J Environ Res Public Health. 2021 Dec 29;19(1):. (PMID: 35010589) Lancet. 2022 Apr 16;399(10334):1513-1536. (PMID: 35279232) Am J Epidemiol. 1978 Jan;107(1):71-6. (PMID: 623091) Lancet. 2022 Jun 25;399(10344):2351-2380. (PMID: 35405084) Health Sci Rep. 2022 Mar 15;5(2):e562. (PMID: 35317419) Lancet Glob Health. 2020 Sep;8(9):e1234-e1241. (PMID: 32711684) Lancet Infect Dis. 2022 Jan;22(1):35-42. (PMID: 34461056) |
معلومات مُعتمدة: | 001 International WHO_ World Health Organization |
فهرسة مساهمة: | Keywords: COVID-19; Epidemiology; Immunity; Mongolia; Pandemics; SARS-CoV-2; Seroepidemiologic studies; Seroprevalence |
تواريخ الأحداث: | Date Created: 20230626 Latest Revision: 20230903 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC10084888 |
DOI: | 10.1016/j.lanwpc.2023.100760 |
PMID: | 37360871 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!